z-logo
open-access-imgOpen Access
Cell-mediated immunity to herpes simplex virus: specificity of cytotoxic T cells
Author(s) -
M. J. P. Lawman,
Richard J. Courtney,
R. Eberle,
P A Schaffer,
Mizuho Ohara,
Barry T. Rouse
Publication year - 1980
Publication title -
infection and immunity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 220
eISSN - 1070-6313
pISSN - 0019-9567
DOI - 10.1128/iai.30.2.451-461.1980
Subject(s) - ctl* , cytotoxic t cell , biology , herpes simplex virus , virology , cytotoxicity , antigen , glycoprotein , virus , microbiology and biotechnology , immunology , in vitro , biochemistry
This communication deals with the question of which of the viral antigens constitutes the targets for cytotoxic T lymphocytes (CTL) generated against herpes simplex virus type 1 (HSV-1). The approach used was, first, to compare cytotoxicity of CTL against target cells infected with virus in the presence of tunicamycin and 2-deoxy-D-glucose, which are known to inhibit glycoprotein synthesis, and second, to compare cytotoxicity of CTL against target cells infected with wild-type HSV-1 with that against target cells infected with a temperature-sensitive mutant of HSV-1 which, at the nonpermissive temperature, exhibits diminished glycoprotein synthesis. The results show that glycoprotein expression is required for the demonstration of cytotoxic activity of CTL. The level of cytotoxicity against the temperature-sensitive HSV-1 target at the nonpermissive temperature was reduced and correlated with the level of expression of the major envelope glycoprotein region (VP123; molecular weight = 123,000) at the target cell surface as measured serologically by antibody binding studies. The results were interpreted to indicate that HSV-1-induced glycoproteins are the target antigens for anti-HSV CTL and that the principal viral antigens recognized by the CTL may be glycoproteins of the VP123 region.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here